Switching between GLP-1 medications

Top switching scenarios

12 editor-curated guides

Highest-intent transitions, each with FDA-sourced washout windows, dose-equivalent tables, side-effect timelines, and prescriber checklists.

Ozempic → Mounjaro
Weight-loss plateau on Ozempic — SURMOUNT-1 showed ~22% body-weight reduction on tirzepatide vs ~15% on semaglutide (STEP-1)
Ozempic → Wegovy
Off-label Ozempic use for weight loss — switching to FDA-approved indication
Ozempic → Zepbound
Ozempic used off-label for weight loss — Zepbound is FDA-approved for obesity
Wegovy → Zepbound
Greater weight-loss potential — SURMOUNT-1 ~22% vs STEP-1 ~15%
Wegovy → Mounjaro
Type 2 diabetes diagnosis — Mounjaro is the T2D-indicated tirzepatide
Mounjaro → Zepbound
Same active ingredient (tirzepatide) — switching for indication match (obesity vs T2D)
Saxenda → Wegovy
Daily injection burden — Wegovy is weekly
Trulicity → Mounjaro
Greater A1C reduction — SURPASS-2 head-to-head: tirzepatide reduced A1C ~2.3% vs semaglutide ~1.9%
Trulicity → Ozempic
Greater A1C reduction — SUSTAIN-7 head-to-head: semaglutide reduced A1C more than dulaglutide
Compounded semaglutide → Wegovy
FDA resolved Wegovy shortage (October 2024) — compounding restrictions tightening
Compounded tirzepatide → Zepbound
FDA removed tirzepatide from shortage list (October 2024) — 503A/503B compounders must wind down
Rybelsus → Ozempic
Greater A1C reduction — injection semaglutide has higher bioavailability than oral

Switching from Ozempic

Switching from Wegovy

Switching from Mounjaro

Switching from Zepbound

Switching from Saxenda

Switching from Rybelsus

Switching from Compounded semaglutide

Switching from Compounded tirzepatide